Association of presence of APLA subtypes, separate for IgG and IgM isotypes, with thrombotic events; persistent versus persistent or transient antibodies
. | Persistent . | . | Persistent or transient . | . | ||
|---|---|---|---|---|---|---|
| APLA subtype . | OR (95% CI) . | P . | OR (95% CI) . | P . | ||
| ACLA IgG | 10.0 (1.8-56) | .013 | 2.8 (0.5-16) | .211 | ||
| ACLA IgM | 32.7 (4.2-256) | .001 | 10.0 (1.8-56) | .013 | ||
| Anti-β2-GPI IgG | 17.3 (2.6-116) | .005 | 10.6 (1.7-65) | .010 | ||
| Anti-β2-GPI IgM | 6.7 (1.2-37) | .036 | 9.2 (1.5-55) | .015 | ||
| Anti-PT IgG | 3.5 (0.7-19) | .155 | 3.1 (0.6-18) | .179 | ||
| Anti-PT IgM | 3.6 (0.3-46) | .358 | 2.6 (0.4-17) | .292 | ||
. | Persistent . | . | Persistent or transient . | . | ||
|---|---|---|---|---|---|---|
| APLA subtype . | OR (95% CI) . | P . | OR (95% CI) . | P . | ||
| ACLA IgG | 10.0 (1.8-56) | .013 | 2.8 (0.5-16) | .211 | ||
| ACLA IgM | 32.7 (4.2-256) | .001 | 10.0 (1.8-56) | .013 | ||
| Anti-β2-GPI IgG | 17.3 (2.6-116) | .005 | 10.6 (1.7-65) | .010 | ||
| Anti-β2-GPI IgM | 6.7 (1.2-37) | .036 | 9.2 (1.5-55) | .015 | ||
| Anti-PT IgG | 3.5 (0.7-19) | .155 | 3.1 (0.6-18) | .179 | ||
| Anti-PT IgM | 3.6 (0.3-46) | .358 | 2.6 (0.4-17) | .292 | ||